Stockreport

TCR² Therapeutics Announces Immuno-Oncology Pioneer Dr. Axel Hoos Joins its Board of Directors

TCR2 Therapeutics Inc.  (TCRR) 
Last tcr2 therapeutics inc. earnings: 11/12 07:00 am Check Earnings Report
PDF CAMBRIDGE, Mass., April 15, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of no [Read more]